PRCT INVESTOR DEADLINE: RGRD Law Files Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who purchased stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements by failing to disclose an extensive discount program that artificially inflated sales and revenues, leading to a significant overstock of handpiece units. Investors with substantial losses have until September 22, 2026, to seek appointment as lead plaintiff in the case.
Kaplan Fox Announces a Securities Class Action Filed Against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) - Lead Plaintiff Deadline is September 22, 2026
Kaplan Fox & Kilsheimer LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece unit sales and revenues by concealing that its discount program caused handpiece orders to materially exceed procedures. Investors who suffered losses are encouraged to contact Kaplan Fox, with a lead plaintiff deadline of September 22, 2026.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) due to alleged undisclosed inventory issues and a significant stock decline. The lawsuit claims PROCEPT withheld crucial information about handpiece sales practices, using an extensive discount program that artificially inflated sales by encouraging bulk orders beyond customer demand. Investors reportedly learned the truth through a series of disclosures that led to a substantial drop in share price.
Attention Long-Term Shareholders of AeroVironment, Inc.
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of AeroVironment, Inc. (NASDAQ: AVAV), PROCEPT BioRobotics Corporation (NASDAQ: PRCT), Roblox Corporation (NYSE: RBLX), and The Simply Good Foods Company (NASDAQ: SMPL). Shareholders who purchased shares before specific dates and still hold them are encouraged to contact the law office to potentially seek corporate reforms, return of funds, and incentive awards. The investigations concern allegations of misleading statements and undisclosed risks regarding company operations and prospects.
PRCT DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
The Rosen Law Firm is reminding purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock during the Class Period (February 28, 2024, and February 25, 2026) of an important lead plaintiff deadline of September 22, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its discount program, which artificially inflated sales and revenues by pulling forward future sales, leading to overstocking and an inability to meet stated sales guidance. Investors who bought PROCEPT common stock during this period may be entitled to compensation and are encouraged to contact the firm.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PROCEPT BioRobotics Corporation (PRCT)
Bernstein Liebhard LLP has announced the filing of a securities fraud class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased shares between February 28, 2024, and February 25, 2026. The lawsuit alleges that the company made false and misleading statements about its business, growth prospects, and financial stability, leading to inflated stock prices and subsequent investor losses. Investors are encouraged to join the class action by September 22, 2026.
Attention Long-Term Shareholders of Cogent Communications
Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Cogent Communications Holdings, Inc. (CCOI), Primoris Services Corporation (PRIM), PROCEPT BioRobotics Corporation (PRCT), and Roblox Corporation (RBLX). The investigations stem from alleged materially false and misleading statements and/or failures to disclose adverse facts, leading to alleged securities fraud class actions against these companies. Shareholders who purchased shares before specific dates and still hold them are encouraged to contact the law office to seek corporate reforms and other remedies.
GSA Capital Partners LLP Purchases New Position in PROCEPT BioRobotics Corporation $PRCT
GSA Capital Partners LLP has acquired a new stake of 49,269 shares in PROCEPT BioRobotics Corporation, valued at approximately $1.11 million. This makes GSA Capital Partners LLP a 0.09% owner of the company. Several other institutional investors also adjusted their positions in PROCEPT BioRobotics, which currently has an average analyst rating of "Hold" and a target price of $28.00.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding inventory issues, specifically that U.S. handpiece sales significantly exceeded procedures, leading to an inventory glut. This disclosure caused Procept's stock to decline by over 18% in two days.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for alleged violations of federal securities laws. The lawsuit claims that Procept failed to disclose material information regarding excess field inventory of handpiece sales, which led to a significant decline in revenue and an over 18% drop in stock price. Investors who purchased shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to apply for lead plaintiff.
PROCEPT sets a Sept. 15 New York date with healthcare investors
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management team will participate in the Baird 2026 Global Healthcare Conference in New York City on September 15, 2026. They will present and host investor meetings at the conference. Following this announcement, the company's stock, PRCT, experienced a moderate negative market reaction, declining by 3.58% to $20.88.
PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
PROCEPT BioRobotics Corporation announced that members of its management team will present and host investor meetings at the Baird 2026 Global Healthcare Conference in New York City on September 15, 2026. The company specializes in surgical robotics for urology, including the AQUABEAM® and HYDROS® Robotic Systems which use AI-powered Aquablation therapy for BPH. They are also conducting research into prostate cancer treatment using their robotic and AI technologies.
The Bull Case For PROCEPT BioRobotics (PRCT) Could Change Following Q2 Losses Amid Strong Revenue Growth
PROCEPT BioRobotics (PRCT) reported strong Q2 2026 revenue growth of US$94.5 million, up from US$79.18 million year-over-year, but also experienced widened net losses of US$26.86 million. Despite these losses, the company maintained its full-year revenue guidance of US$390 million to US$410 million, indicating a continued focus on expanding its Aquablation franchise. This financial update reinforces the company's strategy of tolerating losses to build scale and expand its market beyond benign prostatic hyperplasia, but also highlights the risk of ongoing operating losses.
PRCT DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM,
The Rosen Law Firm is encouraging investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who experienced losses exceeding $100,000 to secure legal counsel before the September 22, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding an undisclosed discount program that artificially inflated sales and revenues, leading to an overstocking of products and significant financial harm. Investors who purchased PROCEPT common stock between February 28, 2024, and February 25, 2026, may be entitled to compensation.
PROCEPT BioRobotics (PRCT) grants RSUs and options to Chief Strategy & Marketing Officer
PROCEPT BioRobotics (PRCT) granted its Chief Strategy & Marketing Officer, Pooja Sharma, 23,622 restricted stock units (RSUs) and an option to purchase 32,681 shares at an exercise price of $21.95 on August 13, 2026. These equity awards are intended to represent 50% of her expected 2027 grant. Following these transactions, Sharma directly holds 111,181 shares of common stock.
PROCEPT BioRobotics (PRCT) awards stock options and RSUs to EVP CTO Templin
PROCEPT BioRobotics has granted its EVP and CTO, Barry L. Templin, 36,312 stock options with an exercise price of $21.95 and 26,246 restricted stock units (RSUs). These equity awards, dated August 13, 2026, are part of his compensation, vesting over four years subject to continued service, and represent 50% of his anticipated 2027 grant. Following the RSU grant, Templin directly holds 95,199 common shares in the company.
PROCEPT BioRobotics (PRCT) awards RSUs and stock options to CFO Kevin Waters
PROCEPT BioRobotics (PRCT) has granted its EVP and CFO, Kevin Waters, 29,527 Restricted Stock Units (RSUs) and a stock option for 40,851 shares. These awards, granted on August 13, 2026, are intended to represent 50% of the value of Waters' expected 2027 equity compensation. The RSUs and options have specific vesting schedules tied to continued service.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who incurred substantial losses to file lead plaintiff applications by September 22, 2026. This securities class action lawsuit alleges that Procept and its executives failed to disclose material information regarding excess inventory of handpiece sales, which materially exceeded procedures from Q1 2023, leading to a significant decline in quarterly sales and an 18% drop in stock price after the company announced its Q4 2025 earnings.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is reminding investors who suffered substantial losses in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to file lead plaintiff applications by September 22, 2026, in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose that its U.S. handpiece sales materially exceeded procedures since Q1 2023, leading to an excess inventory of over 10,000 units. This undisclosed inventory glut resulted in a significant decline in quarterly handpiece unit sales and an 18% drop in stock price after the company announced its Q4 2025 earnings.
Why PROCEPT BioRobotics (PRCT) Could Be 10% Undervalued On Reaffirmed Guidance
PROCEPT BioRobotics (PRCT) is back in focus after reaffirming its full-year guidance following Q2 2026 results, leading to a recent stock price increase despite previous longer-term declines. While a popular narrative suggests the stock is 9.4% undervalued with a fair value of $25.26 per share due to expected growth and profitability, Simply Wall St's DCF model indicates it might be overvalued at $16.95, highlighting mixed signals for investors. The company continues to face net losses but shows strong procedural growth.
67,700 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by Quantinno Capital Management LP
Quantinno Capital Management LP recently acquired 67,700 shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) worth approximately $1.69 million, making it a new stakeholder in the company. Institutional investors collectively own 89.46% of PROCEPT BioRobotics, which faces mixed analyst ratings, a consensus "Hold" with a $28 price target, and recent stock performance issues. Despite a 19.3% year-over-year revenue increase to $94.5 million, the company reported an EPS loss of $0.47, missing estimates, and is also grappling with ongoing legal concerns regarding its sales practices.
PROCEPT BioRobotics Corporation Notice of September 22, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased shares between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT misled investors regarding its handpiece sales practices, particularly by using extensive discount programs to artificially inflate reported unit sales and revenues. Investors suffered substantial losses as partial disclosures about deteriorating sales performance and excess customer inventory drove down the stock price.
PRCT DEADLINE: ROSEN, A LEADING LAW FIRM Encourages PROCEPT
The Rosen Law Firm is encouraging investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who suffered losses exceeding $100K to secure counsel before the September 22, 2026, lead plaintiff deadline. The firm reminds purchasers of PRCT common stock between February 28, 2024, and February 25, 2026, about a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and/or misleading statements regarding an undisclosed discount program that artificially inflated handpiece unit sales and revenues.
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT falsely claimed consistent handpiece unit sales and procedures, when in reality, an undisclosed discount program caused handpiece orders to significantly exceed procedures, artificially inflating sales and revenues. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of September 22, 2026.
PRCT DEADLINE: ROSEN, A LEADING LAW FIRM Encourages PROCEPT BioRobotics Corporation Investors ...
Rosen Law Firm is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who purchased common stock between February 28, 2024, and February 25, 2026, about the September 22, 2026, lead plaintiff deadline. The firm alleges that during this period, Procept made materially false and misleading statements or failed to disclose that it utilized an undisclosed discount program to incentivize bulk orders, artificially inflating reported U.S. handpiece unit sales and revenues. Investors who suffered losses are encouraged to contact Rosen Law Firm to learn more about joining the class action.
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 4.8% - What's Next?
PROCEPT BioRobotics (NASDAQ:PRCT) shares fell 4.8% after reporting mixed Q2 2026 results with revenue growth but a larger-than-expected loss and continued unprofitability. The company faces a class-action lawsuit regarding alleged misleading statements about demand and inventory, adding to investor uncertainty. Despite a CEO stock purchase, analyst sentiment is mixed with downgrades, resulting in a consensus "Hold" rating and an average price target of $28.00.
PRCT Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its U.S. handpiece unit sales and revenue, primarily due to an undisclosed discount program that artificially inflated sales and created a surplus of inventory. Investors with substantial losses during this period have until September 22, 2026, to seek appointment as lead plaintiff.
PROCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that Procept misled investors by failing to disclose an extensive discount program that artificially inflated sales and revenues, leading to an overstock of inventory. Investors who suffered losses are encouraged to contact the law firm to discuss their legal options and apply to be lead plaintiff by September 22, 2026.
Kaplan Fox Encourages Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to Contact the Firm to Learn About Their Legal Rights
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece unit sales and revenues by using undisclosed sales tactics, specifically a discount program that caused handpiece orders to materially exceed procedures. Investors who suffered losses are encouraged to contact Kaplan Fox to learn about their legal rights and the lead plaintiff process, with a deadline of September 22, 2026, to move the court as a lead plaintiff.
Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to join a class action lawsuit. The suit alleges that PROCEPT BioRobotics Corporation made false or misleading statements regarding an undisclosed discount program that inflated sales and revenue, leading to a surplus of inventory and inability to meet sales guidance. Shareholders who purchased PRCT shares between February 28, 2024, and February 25, 2026, are encouraged to contact the firm by the September 22, 2026, deadline to register for the class action.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (Procept) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding handpiece sales materially exceeding procedures, leading to a significant inventory glut and an 18% stock decline. KSF is encouraging affected investors to contact them to discuss their legal rights.
Why PROCEPT BioRobotics (PRCT) Is Up 9.6% After Reaffirming 2026 Revenue Guidance Despite Wider Losses
PROCEPT BioRobotics (PRCT) saw its stock rise 9.6% despite reporting wider net losses in Q2 2026, driven by reaffirming its full-year 2026 revenue guidance of US$390 million to US$410 million. The company's investment narrative centers on Aquablation adoption and the path to sustainable profitability, with analysts noting both optimistic and cautious outlooks regarding future growth, competition, and pricing pressures. The reaffirmed guidance suggests management anticipates continued demand momentum even as losses expand.
PROCEPT BioRobotics (NASDAQ:PRCT) CEO Larry Wood Purchases 23,900 Shares
PROCEPT BioRobotics CEO Larry Wood purchased 23,900 shares of company stock for approximately $498,315. The company recently reported better-than-expected revenue but a slightly wider loss per share, leading to mixed signals from analysts and a recent downgrade from Wells Fargo. PROCEPT BioRobotics also faces a securities-fraud class action lawsuit, adding legal and reputational risks.
Procept BioRobotics CEO Larry Wood buys $498k in stock
PROCEPT BioRobotics CEO Larry Wood recently purchased 23,900 shares of the company's common stock for approximately $498,315, held indirectly through The Larry Wood Trust. This insider buying follows a period of stock momentum and occurs as the company reported a 19% increase in Q2 revenue, although procedure growth was softer than expected, leading analysts to adjust price targets and ratings. The company maintains its fiscal 2026 sales guidance.
PROCEPT BioRobotics (PRCT) CEO adds 23,900 shares via trust purchase
PROCEPT BioRobotics Corp President and CEO Larry L. Wood, through The Larry Wood Trust, purchased 23,900 shares of common stock on August 7, 2026, at a weighted average price of $20.85 per share. Following this transaction, the trust indirectly holds 23,900 shares, and Wood directly holds 314,203 shares, which include shares acquired under the company’s 2021 Employee Stock Purchase Plan. The transaction demonstrates a positive insider sentiment with a high filing impact.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors to ...
The Rosen Law Firm is encouraging investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to join a class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements about an extensive discount program which artificially inflated reported sales and revenue between February 28, 2024, and February 25, 2026. Investors who purchased stock during this period have until September 22, 2026, to move for lead plaintiff.
PROCEPT BioRobotics Corp. Revenue Breakdown – BMV:PRCT
PROCEPT BioRobotics Corp. (BMV:PRCT) generated 5.55 billion MXN in revenue last year. The "Hand Pieces and Other Consumables" segment was the top performer, contributing 3.27 billion MXN, an increase from 2.53 billion MXN the previous year. The United States was the primary revenue source, accounting for 4.87 billion MXN last year, up from 4.18 billion MXN.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who suffered substantial losses to file lead plaintiff applications by September 22, 2026, in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess inventory and a significant decline in handpiece sales, which led to a more than 18% stock drop. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF to discuss their legal rights.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for investors who purchased shares between February 28, 2024, and February 25, 2026. The lawsuit alleges the company failed to disclose that U.S. handpiece sales materially exceeded procedures, leading to a significant inventory glut and a subsequent 18% stock decline. Investors with substantial losses are encouraged to contact KSF by the September 22, 2026 lead plaintiff application deadline.
Kaplan Fox Reminds PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors of a Securities Class Action Deadline on September 22, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece unit sales and revenues by pulling forward demand through undisclosed sales tactics. Investors who suffered losses are encouraged to contact Kaplan Fox by the September 22, 2026 deadline to potentially serve as a lead plaintiff.
ROSEN, A TOP RANKED LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
Rosen Law Firm is encouraging investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to secure legal counsel before the September 22, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false or misleading statements regarding its discount program and its impact on sales, revenues, and inventory levels between February 28, 2024, and February 25, 2026. Investors who purchased common stock during this period may be entitled to compensation.
ROSEN, A TOP RANKED LAW FIRM, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
The Rosen Law Firm is encouraging investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to secure counsel before the September 22, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its discount program and its impact on sales and revenue between February 28, 2024, and February 25, 2026. Investors who purchased common stock during this period may be entitled to compensation.
Kaplan Fox Alerts Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Pending Securities Class Action - Deadline is September 22, 2026
Kaplan Fox & Kilsheimer LLP has announced a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT misled investors by not disclosing that its discount program caused handpiece orders to significantly exceed actual procedures, artificially inflating sales and revenues by pulling forward demand. Investors who suffered losses are encouraged to contact Kaplan Fox, with a deadline of September 22, 2026, to move for lead plaintiff status.
PROCEPT BioRobotics Corp 1Q 2026: Revenue $94.5M, EPS ($0.47) — 10-Q Summary
PROCEPT BioRobotics Corp (PRCT) reported its first-quarter 2026 results, showing revenue growth to $94.5 million, an increase of 19.3% year-over-year. Despite the revenue rise, the company recorded a net loss of ($26.86M) and a diluted loss per share of ($0.47), both widening compared to the prior year. The growth was attributed to higher system, handpiece, and service sales, with an expanded install base and increased commercial and R&D investments.
PROCEPT BioRobotics (PRCT) Stock Rises As Revenue Holds Firm And Losses Deepen
PROCEPT BioRobotics (PRCT) stock rose by 5.8% after its Q2 earnings report, despite widening losses. The company reported Q2 sales of US$94.5m and maintained its full-year revenue guidance, indicating sustained growth. However, net losses deepened to US$26.9m, highlighting the company's challenge in balancing revenue growth with profitability.
[10-Q] PROCEPT BioRobotics Corp Quarterly Earnings Report
PROCEPT BioRobotics Corp. filed its Form 10-Q quarterly report for the period ending June 30, 2026, disclosing a net loss of $58.5 million on revenues of $177.6 million for the first six months of 2026. The company reported $227.9 million in cash and cash equivalents and $52.0 million in debt, with increased common shares due to stock-plan issuances. A class-action lawsuit filed in July 2026 concerning stock purchases between February 2024 and February 2026 remains in early stages with an unestimable loss amount.
Kaplan Fox Notifies PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors of a Securities Class Action Deadline on September 22, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated reported U.S. handpiece unit sales and revenues through undisclosed sales tactics, misleading investors about the consistency between handpiece unit sales and procedures. Investors who suffered losses and wish to serve as lead plaintiff must move the court by September 22, 2026.
PROCEPT BioRobotics reports Q2 2026 revenue $94.5M, net loss $26.9M, reiterates FY26 revenue guide
PROCEPT BioRobotics reported Q2 2026 revenue of $94.5 million and a net loss of $26.9 million, while reiterating its full-year 2026 revenue guidance of $390 million to $410 million. The company achieved a 19% year-over-year revenue increase, with U.S. procedures growing by approximately 21% and international revenue up 15%. Key business highlights included the delivery of 65 U.S. HYDROS systems and strengthened recommendations for its Aquablation therapy.
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Beats Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) reported a Q2 loss of $0.47 per share, slightly wider than the Zacks Consensus Estimate of a $0.46 loss, marking an earnings surprise of -2.17%. Despite the loss, the company surpassed revenue expectations, posting $94.5 million against an estimated $92.5 million. PRCT shares have underperformed the S&P 500 year-to-date and currently hold a Zacks Rank #4 (Sell), suggesting potential underperformance in the near future.
Procept Biorobotics earnings in spotlight as growth questions loom
Procept Biorobotics (NASDAQ:PRCT) is set to report second-quarter earnings, with investors focused on procedure growth amidst legal scrutiny and competitive pressures. Analysts anticipate a loss of 46 cents per share on revenue of $92.6 million, representing 17% year-over-year growth. The company faces class-action lawsuits regarding bulk-order discounting and competition from prostatic artery embolization, while progress on its WATER IV clinical trial could be a long-term growth driver.
